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Abstract
Background: Studies about the biology, treatment pattern, and treatment outcome of metastatic/recurrent
neuroendocrine tumor (NET) have been few.
Methods: We enrolled patients with metastatic/recurrent NET diagnosed between January 1996 and July 2007 and
retrospectively analyzed.
Results: A total of 103 patients were evaluated. Twenty-six patients (25.2%) had pancreatic NET, 27 (26.2%) had
gastrointestinal NET, 2 (1.9%) had lung NET, 28 (27.2%) had NET from other sites, and 20 (19.4%) had NET from
unknown origin. The liver was the most common metastatic site (68.9%). Thirty-four patients had grade 1 disease, 1
(1.0%) had grade 2 disease, 15 (14.6%) had grade 3 disease, 9 (8.7%) had large cell disease, and 7 (6.8%) had small
cell disease.
Sixty-six patients received systemic treatment (interferon, somatostatin analogues or chemotherapy), 64 patients
received local treatment (TACE, radiofrequency ablation, metastasectomy, etc.). Thirty-six patients received both sys-
temic and local treatments.
Median overall survival (OS) was 29.0 months (95% confidence interval, 25.0-33.0) in the103 patients. OS was signifi-
cantly influenced by grade (p = .001). OS was 43.0, 23.0, and 29.0 months in patients who received local treatment
only, systemic treatment only, and both treatments, respectively (p = .245). The median time-to-progression (TTP)
was 6.0 months. Overall response rate was 34.0% and disease-control rate was 64.2%. TTP was influenced by the
presence of liver metastasis (p = .011).
Conclusions: OS of metastatic/recurrent NET was different according to tumor grade. TTP was different according
to metastasis site. Therefore, development of optimal treatment strategy based on the characteristics of NET is
warranted.
Background
In 1890, Ransom described a patient with a carcinoid
syndrome and liver metastasis, which was the first
report of metastatic neuroendocrine tumor (NET) [1].
Radical surgery has been the only available cure for
NETs although more than 50% of these tumors are
unresectable at diagnosis. And once metastasis presents,
NET is usually not curable with their clinical courses
being diverse from relatively indolent to aggressive.
In the case of unresectable metastatic NETs, they has
been treated with either local treatment modalities or
systemic treatment modalities according to location and
burden of metastasis or tumor biology [2]. Systemic
treatment including interferon (IFN)-a, somatostatin
analogues, and chemotherapy mainly with streptozotocin
has been considered palliative and shown only modest
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modalities such as palliative surgery, transcatheter arter-
ial chemoembolization (TACE), and radiofrequency
ablation (RFA) have been frequently utilized in the
metastatic setting, especially for liver metastasis.
Because metastatic/recurrent NET is a rare disease,
randomized controlled trials have been lacking. How-
ever, incidence of NET is increasing according to the
recent US Surveillance, Epidemiology, and End Results
(SEER) report which is the largest population-based
study to date [5]. Recently with an increased under-
standing of the biology of NETs, it has been possible to
actively investigate novel agents and treatments includ-
ing targeted therapy with some of them proven to be
effective [6,7].
Many studies for malignant NETs were done mainly
in Western countries while only few have been done in
Asian countries. Besides, studies about the biology,
treatment pattern, and treatment outcome of metastatic/
recurrent NET have been few and far between other
than early-stage NET. Therefore we conducted this
study to reveal the biologic characteristics and treatment
outcomes of metastatic/recurrent NET in a referral cen-
ter in an Asian country.
Methods
We consecutively enrolled patients with histologically
confirmed metastatic/recurrent NET between January
1996 and July 2007 at Seoul National University Hospi-
tal. Medullary carcinoma of thyroid, pheochromocy-
toma, paraganglioma, small-cell and large-cell
neuroendocrine carcinoma of the lung, and adrenal cor-
tical carcinoma were excluded in this analysis because
t h o s eh a v eu n i q u ec h a r a c t e r i s t i c s .W er e t r o s p e c t i v e l y
analyzed the characteristics of these population, treat-
ment pattern, and treatment outcomes.
Data about stage before progression to metastatic dis-
ease or recurrence was obtained. A localized NET was
defined as an invasive neoplasm confined entirely to the
organ of origin. A regional NET was defined as a neo-
plasm that extended beyond the limits of the organ of
origin directly into surrounding organs or tissue or a
neoplasm involving regional lymph nodes. Finally, a
metastatic NET was defined as a neoplasm that spread
to parts of the body remote from the primary tumor [5].
There has been no established uniform grading system
for NETs. We classified “carcinoid tumors” or “islet cell
tumors” or well differentiated tumors into grade 1, aty-
pical carcinoid or moderately differentiated tumors into
g r a d e2 ,p o o r l yd i f f e r e n t i a t e dt u m o r si n t og r a d e3 ,a n d
anaplastic tumors into grade 4 according to the SEER
[5]. In addition, there were large-cell and small-cell neu-
roendocrine carcinomas from sites other than the lung
and from unknown primary origin. These were also
included in our analysis.
To evaluate response to systemic treatment, RECIST
(response evaluation criteria in solid tumors) criteria
were applied. Statistical analyses were performed using
t h ec h i - s q u a r ea n dt h eF i s h e r ’s exact test to compare
response of systemic treatment. The Kaplan-Meier
method was used to estimate overall survival (OS) and
the time-to-progression (TTP) after systemic treatment.
In multivariate analyses for survival, Cox regression ana-
lysis was used. Statistical significance was achieved if the
probability was less than 5% (p < .05). We received
approval for this study from the Institutional Review
Board of Seoul National University Hospital (IRB No.
H-0809-039-256).
Results
(1) Baseline characteristics
Table 1 includes the baseline characteristics for the
whole population. A total of 103 patients were enrolled.
The median duration of follow-up was 40.0 months
(range, 0.0-159.0). The median age was 54 years (range,
22-78). There were 58 (56.3%) males.
Twenty-six patients (25.2%) were diagnosed with pan-
creatic NET, 27 patients (26.2%) with GI NET, and 2
patients (1.9%) with lung NET. Tumors that originated
from sites other than the pancreas, GI tract, and lung
were observed in 28 patients (27.2%). There were 20
patients (19.4%) of whom the origin of the tumor was
unknown. In GI NET, 11 cases (40.7%) were foregut
NET, 1 case (3.7%) was midgut NET, and 15 cases
(55.6%) were hindgut NET. As an initial site of metasta-
sis, the liver was the most common site (50 patients,
74.6%). As a site of recurrence, the liver was also the
most common site (16, 44.4%).
Sixty-seven patients were diagnosed with metastatic
disease from their initial diagnosis, 30 patients had
recurrent disease after curative resection and 6 patients
had disease which progressed to metastatic disease from
a non-metastatic disease state after initial diagnosis.
Regarding the grade classification of NET, 34 patients
(33.0%) had grade 1 disease, 1 patient (1.0%) had grade
2 disease, 15 patients (14.6%) had grade 3 disease, 9
patients had (8.7%) large cell disease, and 7 patients
(6.8%) had small cell disease. Grade was unclassified in
25 patients (24.3%) and information about grade was
unavailable in 12 patients (11.7%).
At the time of diagnosis of metastatic/recurrent dis-
ease, the median value of 5-hydroxyindoleacetic acid (5-
H I A A )f r o m2 4 - h o u ru r i n es a m p l e sw a s2 3 . 0μmol/day
(range, 2.6-1324.6) and the median value of serum levels
for neuron-specific enolase (NSE) was 1.6 nmol/l (range,
0.4-23.1).
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Page 2 of 11Table 1 Baseline characteristics of 103 patients
Characteristic Frequency %
Median (years) 54 (range, 22-78)
Age <60 63 61.2
≥ 60 40 38.8
Sex Male 58 56.3
Female 45 43.7
Absent 92 89.3
Carcinoid symptom Present 5 4.9
Unavailable 6 5.8
Pancreas 26 25.2
GI tract 27 26.2
Foregut 11 10.7
Midgut 1 1.0
Origin Hindgut 15 14.6
Lung 2 1.9
Etc.* 28 27.2
Unknown 20 19.4
Initial metastatic site Liver 50 74.6
Bone 12 17.9
Lung 12 17.9
Brain 3 4.5
Lymph node 20 29.9
Etc. 10 14.9
Recurrent site Liver 15 41.7
Bone 16 44.4
Lung 1 2.8
Brain 1 2.8
Lymph node 15 41.7
Etc. 3 8.3
Local 21 21.4
Prior stage Regional 15 14.6
Distant 67 65.0
1 34 33.0
2 1 1.0
Grade 3 15 14.6
Large 9 8.7
Small 7 6.8
Unclassified 25 24.3
Unavailable 12 11.7
Median (range) 23.0 (2.6-1324.6)
24-hour urine 5-HIAA (μmol/day)
† <31.4 (reference range) 15 71.4
Biomarkers ≥ 31.4 6 28.6
Median (range) 1.6 (0.4-23.1)
Serum NSE (nmol/l)
‡ <1.0 (reference range) 12 36.4
≥ 1.0 21 63.6
GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase
* The biliary tract (5 cases), thymus (4), uterus (4), mediastinum (3), oral cavity (2), skin (2), trachea (1), liver (1), kidney (1), pelvis (1), prostate (1), bladder (1),
nasal cavity (1), and orbit (1)
† Available data: 21
‡ Available data: 33
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metastatic/recurrent NET
Figure 1 shows OS in all of the 103 patients. Median OS
was 29.0 months (95% confidence interval [CI], 25.0-
33.0). The three-year survival rate was 39.2%. Table 2
shows OS according to characteristics. Survival was not
significantly different by age (p = .053), sex (p = .461),
carcinoid symptom (p = .646), primary tumor origin
(p = .660), presence of liver metastasis (p = .995), eleva-
tion of biomarkers (p = .653 for urine 5-HIAA; p =. 0 5 1
for serum NSE), and treatment modality (local treat-
ment only vs. systemic treatment only vs. both treat-
ments, p = .245). Figure 2 illustrates OS according to
treatment modality.
Figure 1 Overall survival in 103 patients
Table 2 Overall survival according to characteristics (n = 103)
Characteristic Median OS 95% CI 3-year
survival
rate (%)
P-value
Age
<60
≥ 60
32.0
27.0
20.9-43.1
12.6-41.4
44.2
31.0
.053
Sex
Male
Female
29.0
31.0
20.5-37.5
26.7-35.3
36.4
42.9
.461
Carcinoid symptom
Absent
Present
29.0
28.0
23.3-34.7
23.7-32.3
40.5
-
.646
Pancreas 43.0 23.4-62.6 45.3
Origin GI 40.0 10.3-69.7 51.2 .660
Lung 10.0 - -
Liver metastasis
Absent
Present
29.0
29.0
18.6-39.4
22.8-35.2
42.2
38.1
.995
1 78.0 32.3-123.7 65.8
Grade 2-3 18.0 1.9-34.1 29.8 .001
Large 15.0 2.8-27.2 13.9
Small 18.0 7.1-28.9 17.9
24-hour urine 5-HIAA (μmol/day) <31.4 31.0 24.3-37.7 42.8 .653
≥ 31.4 46.0 - 66,7
Biomarkers
Serum NSE (nmol/l) <1.0 31.0 - 47.7 .051
≥ 1.0 7.0 4.3-9.7 26.8
Local treatment only 43.0 23.1-62.9 53.0
Treatment modality Systemic treatment only 23.0 0.4-45.6 38.0 .245
Both treatments 29.0 23.6-34.4 43.0
OS, overall survival; CI, confidence interval; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase
Figure 2 Overall survival by treatment modality
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Page 4 of 11OS was significantly influenced by grade (p = .001)
(Figure 3). The significance was derived from the differ-
ence between grade 1 NET and the others (grade 2/3,
large-cell, and small-cell disease) (78.0 months vs. 18.0
months, respectively).
(3) Patterns of treatment
As an initial treatment of metastatic/recurrent disease
setting, systemic treatment was the most common (43
patients, 41.7%), followed by TACE (21, 20.4%), surgery
(13, 12.6%), best supportive care (10, 9.7%), endoscopic
removal (6, 5.8%), and radiotherapy (4, 3.9%).
In the entire course of the disease, 66 patients received
systemic treatment (IFN, somatostatin analogues, and
chemotherapy), 64 patients received local treatment to
the metastatic/recurrent site (TACE, RFA, metastasect-
omy, endoscopic removal, and radiotherapy). Thirty-six
patients received both of systemic and local treatment
and 9 patients received best supportive care only.
A. Systemic treatment in metastatic/recurrent NET
Among the 103 patients, 66 patients received palliative
systemic treatment. Median time from diagnosis of
metastatic/recurrent NET to initiation of systemic treat-
ment was 0.0 months (range, 0.0-77.0). The median line
of systemic treatment which was administered was the
2 lines (range, 1st-7th). Among 66 patients receiving the
1st-line systemic treatment, 36 patients received 2nd-
line systemic treatment, and among them, 22 patients
received 3rd-line systemic treatment. Baseline character-
istics among the 66 patients who received palliative
systemic treatment are demonstrated in Table 3.
Median OS for the 66 patients was 25.0 months (95%
CI, 18.6-31.4). The three-year survival rate was 32.6%.
A sa1 s t - l i n es y s t e m i ct r e a t m e n t ,I F Nw a sa d m i n i s t e r e d
to 15 patients (22.7%), somatostatin-analogue to
2 patients (3.0%), and chemotherapeutic agent to
49 patients (74.2%). Drugs which were administered are
shown in Table 4.
The median TTP after 1st-line systemic treatment was
6.0 months (95% CI, 3.3-8.7). One-year progression-free
rate was 30.2% (Figure 4). Overall response rate (ORR)
was 34.0% (CR, 3.8%; PR, 30.2%; 95% CI, 20.8-47.1) and
disease-control rate (DCR) was 64.2% (95% CI, 50.8-
77.5) in the 1st-line systemic treatment.
A sa2 n d - l i n es y s t e m i ct r eatment, 2 patients (5.6%)
received somatostatin-analogues and 34 patients (94.4%)
received chemotherapy. The median TTP after 2nd-line
systemic treatment was 5.0 months (95% CI, 3.5-6.5).
One-year progression-free rate was 14.1%. ORR was
21.4% and DCR was 53.6%.
As a 3rd-line systemic treatment, 1 patient (4.5%)
received IFN and 21 patients (95.5%) received che-
motherapeutic agents. The median TTP was 2.0 months
(95% CI, 1.5-2.5). One-year progression-free rate was
5.5%. ORR was 12.5% and DCR was 31.3%.
T a b l e s5a n d6s h o wO S ,T T P ,O R R ,a n dD C R
according to the characteristics of the 66 patients.
Although OS was not significantly different according to
treatment modality (p = .350), OS in patients who
received only systemic treatment and not local treat-
ment (23.0 months) seemed to be shorter than the
patients who received both local and systemic treatment
(29.0 months). OS was different between grade 1 (36.0
months) and the others (17.0 months), although insig-
nificant (p = .215).
TTP was influenced by the presence of liver metastasis
(p = .011). The median TTP in the group without liver
metastasis was 12.0 months and in the group with liver
metastasis was 4.0 months (Figure 5).
There was a relationship between ORR and the pre-
sence of liver metastasis (p = .009) or the elevation of
serum NSE (p = .034). DCR was not significantly related
to any clinical factors.
B. Local treatment in metastatic/recurrent NET
Twenty-five patients received TACE. Median number of
TACE was 4 times (range 1-16). Median time interval of
TACE was 3.0 months (range, 0.0-72.0). Six patients
received RFA. Median number of RFA was 1 time
(range 1-2). Metastasectomy was done to 6 patients.
Radiotherapy was given to 15 patients except for pallia-
tive radiotherapy of bone metastasis. Five patients had
their tumors endoscopically removed.
Discussion
This study presented the characteristics and treatment
outcomes of metastatic/recurrent NET. In our study, the
origins of metastatic/recurrent NET was found in
diverse places in the body and grade 1 disease was the
most common (33.0%). Median OS was 29.0 months in
all of the 103 cases. Median OS for 66 patients who
received palliative systemic treatment was 25.0 months.
Figure 3 Overall survival by grade
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which reported an OS of 25.0 months for metastatic
NET among Asians and Pacific islanders. The median
TTP after 1st-line systemic treatment was 6.0 months
with various regimens. Overall response rate (ORR) was
34.0% and disease-control rate (DCR) was 64.2% in the
1st-line systemic treatment.
The grade has been known to be prognostic in sev-
eral studies [5,8,9]. OS was significantly influenced by
the grade in our study (p = .001). Grade 1 tumors
showed longer OS than the others. On the contrary,
higher grade predicted better response after systemic
chemotherapy in several studies [2,10], while not in
others [11].
There are a few reports that revealed the similarity of
the natural course and treatment outcome between
small cell and poorly differentiated neuroendocrine car-
cinoma [12], or between high-grade non-small cell
neuroendocrine carcinoma of lung and small-cell lung
cancer [13]. In our study also, grade-3, large cell, and
small cell NET did not show any difference in OS.
There has been no established uniform grading system
for NETs. Recently WHO (World Health Organization)
or ENET (European Neuroendocrine Tumor Society)
grading systems are available. WHO suggested a grading
system for gastoenteropancreatic NETs. However, the
grading system is not compatible with grading system in
lung NETs (typical carcinoid, atypical carcinoid, large
cell neuroendocrine carcinoma, and small cell lung can-
cer). ENETS proposed grading systems for foregut, mid-
gut and hindgut NETs those are composed of mitotic
count and Ki-67 index. Because our data dealt with
Table 3 Baseline characteristics among the 66 patients who received palliative systemic treatment
Characteristic Frequency %
Median (years) 54 (range, 22-78)
Age <60 42 63.6
≥ 60 24 36.4
Sex Male 41 62.1
Female 25 37.9
Absent 61 92.4
Carcinoid symptom Present 3 4.5
Unavailable 2 3.0
Pancreas 2 3.0
GI 15 22.7
Origin Lung 15 22.7
Etc.* 22 33.3
Unknown 12 18.2
Local 10 15.2
Prior stage Regional 9 13.6
Distant 47 71.2
Grade 1 20 30.3
2 1 1.5
3 10 15.2
Large 8 12.1
Small 5 7.6
Unclassified 15 22.7
Unavailable 7 10.6
24-hour urine 5-HIAA (μmol/day)
† Median (range) 33.5 (6.8-341.2)
<31.4 5 45.5%
Biomarkers ≥ 31.4 6 54.5%
Median (range) 1.36 (0.2-23.1)
Serum NSE (nmol/l)
‡ <1.0 8 36.4%
≥ 1.0 14 63.6%
Abbreviations as in table 1, 2
*The uterus (4 cases), biliary tract (3), thymus (3), mediastinum (2), oral cavity (2), skin (2), trachea (1), kidney (1), prostate (1), bladder (1), nasal cavity (1), and
orbit (1)
† Available data: 11
‡ Available data: 22
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cient number of Ki-67 data, we followed the analysis
method used in the SEER report, which included NETs
from most sites and classified NETs into 4 grade groups
(Grade 1-4). We used it also to compare our results
with SEER report.
Presence of liver metastasis was related to shorter
TTP (p = .011) and lower ORR (p = .009) in our study.
Presence of liver metastasis tended to be related to a
worse response to chemotherapy. A relationship
between liver metastasis of NET and response to che-
motherapy has rarely been reported before. Further
study is required to fully understand the implications of
this result. In this case, it suggests a possible role for
local treatment modalities in the treatment of NET
patients with liver metastasis.
On the contrary, the presence of liver metastasis was
not related to OS in our study. The presence of liver
metastasis was reported as a negative prognostic factor
among all stages of NET in some studies [14], while it
has seldom been studied as a prognostic factor among
metastatic NETs as in our study.
Urinary 5-HIAA [15] and serum NSE [9] have been
well known as a prognostic factor. Patients whose serum
NSE level was elevated showed a shorter OS in our
study although statistically insignificant (p =. 0 5 1 ) .A n d
elevation of serum NSE (p = .034) was related to a
higher ORR. More research should be done to further
explore this relationship between serum NSE and
response to chemotherapy.
In metastatic disease, pancreatic NET has been gener-
ally known to have a poor prognosis compared to GI
NET [16]. Pancreatic NET has been known to be more
chemosensitive than GI NET [3,17]. Comparison of sur-
vival and treatment outcome between pancreatic, GI
and lung NET in a metastatic setting has rarely been
done yet. Treatment outcome after systemic treatment
was not statistically different according to the origins of
the primary tumor found in the pancreas, GI tract, or
lungs in this study.
Patients received either local treatment modalities or
systemic treatment modalities or both. Local treatment
modalities such as TACE, metastasectomy, endoscopic
removal, and radiotherapy were given actively in the
course of treatment. Whatever treatment modalities
patients received did not influence patients’ survival in
our study. However, tendency to survive the longest was
observed in patients who received local treatment only,
followed by patients who received both treatments. In a
subgroup analysis within the 3 groups, the systemic
treatment group was related to high grade (p = .037)
and extrahepatic metastasis (p = .015) (Table 7).
Recently in a large retrospective study, the role of sur-
gery was demonstrated in distant pancreatic NET [18].
However, there have been few studies which compared
local with systemic treatment modalities or systemic
with both treatment modalities in a randomized con-
trolled setting [19].
Regimens used in systemic treatment were diverse in
this study. Eleven patients received biotherapy such as
IFN and somatostatin analogues as the 1st-line. How-
ever, which kind of biotherapy or chemotherapy they
received did not have any relationship to treatment out-
come and survival in our study.
IFN-a has been used for treatment of patients with
NETs for more than 20 years [20,21]. However, its anti-
tumor efficacy has not been satisfactory [22,23].
Table 4 Drugs which were used in the 1st line
Drugs Number
Interferon 15
Somatostatin-analogues 2
EP, EC 16
CAV 3
TC, TP, DP, DC 4
VIP 6
Adriamycin+streptozotocin 2
FOLFOX, XELOX 2
FP, FC 4
IP 1
5-FU+adriamycin+streptozocin 2
Dacarbazine 1
Sunitinib 5
RAD001 3
Total 66
EP, etoposide and cisplatin; EC, etoposide carboplatin; CAV,
cyclophosphamide, adriamycin and vincristine; TC, paclitaxel and carboplatin;
TP, paclitaxel and cisplatin; DP, docetaxel and cisplatin; DC, docetaxel and
carboplatin; VIP, etoposide, ifosfamide and cisplatin; FOLFOX, 5-fluorouracil (5-
FU), leucovorin and oxaliplatin; XELOX, capecitabine, oxaliplatin; FP, 5-FU and
cisplatin; FC, 5-FU and carboplatin; IP, irinotecan and cisplatin; RAD001,
everolimus
Figure 4 Time-to-progression in 66 patients in the 1st line
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Page 7 of 11Somatostatin analogues have been considered mainly an
antisecretory drug for symptom control in NET and its
ability to control the growth of NET has been a matter
of debate [22]. Recently, a result from a randomized
controlled trial was reported which demonstrated favor-
able response and prolongation of TTP after use of
somatostatin analogues in well-differentiated midgut
NET [24].
Table 5 Overall survival and time-to-progression (n = 66)
Characteristic OS*
(months)
95%
CI
1-year survival
rate (%)
P-
value
TTP
(months)
95%
CI
1-year survival
rate (%)
P-
value
Age
<60
≥ 60
26.0
25.0
18.9-
33.1
14.2-
35.8
69.2
69.9
.656
6.0
6.0
2.8-
9.2
0.8-
11.2
26.9
35.4
.611
Sex
Male
Female
22.0
27.0
15.9-
28.1
19.3-
34.7
69.1
69.6
.134
6.0
6.0
0.0-
14.2
2.7-
9.3
28.0
34.6
.771
Pancreas 28.0 18.0-38.0 77.1 .981 7.0 0.0-15.0 41.6
Origin GI 22.0 0.0-
46.9
63.2 2.0 0.8-
3.2
25.0 .258
Lung 9.0 - 50.0 1.0 - -
Liver
metastasis
Absent
Present
25.0
22.0
20.8-
29.2
13.3-
30.7
77.0
65.0
.310
12.0
4.0
9.2-
14.8
1.3-
6.7
40.7
23.8
.011
1 36.0 13.2-
58.8
72.4 12.0 8.3-
15.7
57.5
2-3 17.0 1.1-
32.9
53.0 .612 4.0 1.2-
6.8
34.3
Grade .681
Large 12.0 0.0-
29.8
50.0 2.0 0.0-
4.5
45.0
Small 17.0 10.1-
23.9
100.0 12.0 2.6-
21.4
30.0
24-hour urine 5-HIAA
(μmol/day)
<31.4 20.0 0.0-
52.2
60.0 .114 1.0 - - .045
≥
31.4
40.0 - 62.5 12.0 0.0-
29.6
44.4
Biomarkers
Serum NSE (nmol/l) <1.0
≥ 1.0
25.0
6.0
18.0-
32.0
0.0-
18.0
75.0
46.4
.170
2.0
4.0
0.9-
3.1
1.2-
6.8
0.0
22.2
.381
IFN 36.0 22.6-
49.4
86.7 .169 10.0 0.0-
25.6
22.9
Regimen Somatostatin-analogue
† 3.0 . 50.0 0.0 - - .057
Chemotherapy 20.0 13.3-
26.7
64.5 6.0 3.6-
8.4
34.2
Treatment
modality
Systemic treatment only
Systemic+local treatment
23.0
29.0
0.4-
45.6
23.6-
34.4
57.9
86.1
.350
OS, overall survival; TTP, time-to-progression; CI, confidence interval; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon
*OS was estimated after initiation of systemic treatment except in treatment modality where OS was calculated after diagnosis of metastasis.
†Somatostatin-analogue was given to only 2 patients.
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Page 8 of 11The standard chemotherapy for pancreatic NET has
been a combination of adriamycin and streptozotocin
and to a lesser extent a combination of 5-fluorouracil
(5-FU) and streptozotocin [3]. Although 5-FU and strep-
tozotocin have shown modest antitumor effect, there
has been no clear standard chemotherapy for carcinoid
tumors [23,25]. Some reports have suggested a higher
chemosensitivity of undifferentiated or poorly differen-
tiated NET with etoposide-cisplatin combination [2,26].
Recently, several new agents including target agents
are actively being tried for advanced NET. Sunitinib
showed 16.7% of ORR and 68% of DCR in pancreatic
NETs in a nonrandomized study [27]. In a phase II trial,
everolimus (RAD001) and octreotide long-acting repea-
table (LAR) showed 22% of ORR and 70% of DCR in
advanced low to intermediate-grade NETs [7]. Besides
these drugs, cytotoxic chemotherapy including a capeci-
tabine-oxaliplatin combination [11] also showed modest
antitumor activities in advanced NETs. Radiolabeled
somatostatin analogues have been tried actively and
showed modest antitumor activities [28,29].
In our analysis, there are several limitations. This was
a retrospective study so information such as carcinoid
syndrome and biochemical features was not available in
all of the patients. And the data pool was heterogeneous
and the used regimens were diverse, even though the
relative rarity of NETs makes it difficult to collect suffi-
cient numbers of homogenous groups.
Table 6 Overall response rate and disease-control rate (n = 66)
Characteristic ORR (%) P-value DCR (%) P-value
Age
<60
≥ 60
35.3
31.6
.784
61.8
68.4
.628
Sex
Male
Female
30.3
40.0
.470
69.7
55.0
.279
Pancreas 35.7 71.4
Origin GI 30.8 1.000 38.5 .055
Lung 0.0 0.0
Liver metastasis
Absent
Present
58.8
22.2
.009
82.4
55.6
.072
1 33.3 66.7
2-3 44.4 66.7
Grade .460 .433
Large 40.0 40.0
Small 33.3 100.0
24-hour urine 5-HIAA (μmol/day) <31.4
≥ 31.4
0.0
33.3
.455
20.0
66.7
.242
Biomarkers
Serum NSE (nmol/l)
<1.0
≥ 1.0
0.0
55.6
.034 28.6
77.8
.126
IFN 23.1 53.8
Regimen Somatostatin-analogue* 0.0 .400 0.0 .079
Chemotherapy 39.5 71.1
ORR, overall response rate; DCR, disease-control rate; GI, gastrointestinal; 5-HIAA, 5-hydroxyindoleacetic acid; NSE, neuron-specific enolase; IFN, interferon
*Somatostatin-analogue was given to only 2 patients.
Figure 5 Time-to-progression according to presence of liver
metastasis
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Page 9 of 11Other limitation is that we did not analyze the prog-
nosis and response to systemic treatment according to
the Ki67 status of tumors. The Ki67 is being regarded as
an important prognostic factor which demonstrates the
proliferative capacity of tumors [30]. In our patient pool,
there was no available full data on Ki67. Furthermore,
we did not have data about serum chromogranin A, of
which the clinical meaning and importance are being
highlighted nowadays, because this study was a retro-
spective research composed of patients from 1996.
Further study on NET should harbor the contents of
Ki67 and chromogranin A.
Nevertheless, this study has several strong points.
There have been few reports which dealt with meta-
static/recurrent NET as a whole group and showed the
treatment outcomes. And we tried to search for predic-
tive factors after palliative systemic treatment. Further-
more, we described the treatment patterns and
outcomes in terms of continuum of care. And, as far as
we know, this is one of the largest studies which have
been done to date with this disease group in Asian
countries.
Conclusions
OS of metastatic/recurrent NET was different according
to tumor grade and TTP was different according to
metastasis site. Therefore, development of optimal treat-
ment strategy based on the characteristics of NET as
well as new active agents is warranted.
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